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SUMMARY
To investigate the effectiveness of the influenza vaccine in a population of elderly outpatients, we compared the occurrence and
frequency of influenza like illness (ILI), respiratory illness and hospitalization in vaccinated and non-vaccinated subjects. All the
outcomes were clinically defined. The two groups were similar with respect to demographics, health situation and habits. The influenza
vaccine contributed to the protection of the elderly investigated, since the vaccinated subjects referred a significantly lower number of
ILI than the non-vaccinated. There is a need for more studies about the effectiveness of the influenza vaccine in our country in elderly
and other groups of our population.
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INTRODUCTION
Influenza is an acute respiratory illness characterized by fever,
myalgia, cough and headache. The aetiologic agent is an Orthomyxovirus,
and three serotypes, A, B and C, are known to cause human illness. The
disease lasts, in median, for three days, but cough and malaise can persist
for weeks. Complications of influenza include bronchitis and pneumonia,
besides otitis media and exacerbation of chronic respiratory disease15.
The virus consists in an RNA core and a protein envelope. It has a
marked capacity to mutate its external antigenic composition, thus
escaping the host immune defenses. Minor changes in virus antigenic
composition cause local epidemics. Pandemics arise when major changes
in antigenic composition occur. Pandemics are thought to originate at
the Far East, where humans, pigs and avian live in close proximity6,9.
Climate, humidity and life-style are other factors associated to the
occurrence of the influenza.
The excessive morbidity and mortality, expressed as pneumonia,
excessive hospitalization and death among elderly and patients with
chronic medical conditions are described as the most serious result of
influenza epidemics.
The World Health Organization leads a worldwide Program of
Prevention of Influenza, through a network of laboratories that provides
surveillance and identification of influenza virus isolates from different
continents.
The Regional Group of Observation of Influenza (GROG) started
its activities in 1995, in Brazil. Besides WHO, the GROG, now designated
as “Grupo de Vigilância Epidemiológica da Gripe (VIGIGRIPE)” is
responsible for the surveillance of the Influenza in Brazil. The number
of specimens isolated and the viral identification is improving every
year. In 1999 the VIGIGRIPE collected 1599 specimens and identificated
239 type A and 21 type B influenza virus16.
In order to formulate the vaccine, viruses from all over the world are
evaluated and, in February for the northern hemisphere, and in September
for the southern hemisphere, the WHO publishes which strains of
Influenza virus will likely predominate in the next season.
The influenza vaccine is effective in elderly and patients with chronic
medical conditions, as it has been demonstrated by different studies,
many of them from the northern hemisphere2,11.
The aim of this study was to investigate the level of protection
conferred by the influenza vaccine in elderly outpatients from the city
of São Paulo, Brazil.
SUBJECTS AND METHODS
This retrospective study was held during the 2000 annual campaign
of vaccination against influenza. Individuals 60 years or older who sought
the Immunization Center, located at the “Hospital das Clínicas da
Faculdade de Medicina da Universidade de São Paulo”, in São Paulo
city, for influenza vaccine, were enrolled. A questionnaire containing
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information on demographics, health conditions such as diabetes mellitus,
systemic arterial hypertension (sah), chronic obstructive pulmonary
disease (copd), asthma, bronchitis, pulmonary emphysema, previous
respiratory disease, hematological disease, neoplasm, therapeutic with
corticosteroids, tobacco and alcohol use and influenza vaccination in
1999 was applied. The same two investigators applied all the
questionnaires. All the answers were registered.
The primary outcomes measured refer to the comparative occurrence,
in the previous 12 months, of influenza like illness (ILI), characterized
as fever, cough, myalgia and headache, frequency of ILI, respiratory
illness defined as any other disease than ILI compromising the respiratory
system, hospitalization and hospitalization for respiratory diseases. All
outcomes were clinically defined. No laboratory tests were applied to
confirm reported episodes of ILI.
Statistical analysis: Subjects vaccinated against influenza in 1999
were compared with those non-vaccinated with respect to all variables
described above. The Pearson 2 and the t-test were used to assess
differences in proportions and medians of discrete and continuous data.
A confidence level of 95%, with p < 0.05 was considered statistically
significant.
RESULTS
In this study 187 subjects were enrolled. Of these 70.1% (131) had
received influenza vaccine in 1999. The composition of the vaccine used
in 1999 was A/Sydney/5/97(H2N3); A/New Caledonia/20/29(H1N1);
B/Beijing/184/93.
The vaccinated and non-vaccinated subjects did not differ with respect
to sex, age, presence of underlying diseases, tobacco and alcohol use
(Table 1).The only significant difference was in the number of episodes
of influenza like illness (ILI). The vaccinated subjects referred less
episodes of ILI than the non-vaccinated ones (Table 2).
DISCUSSION
Our study focused on the association of vaccination against influenza
and the occurrence and frequency of clinically defined influenza like-
illnesses, respiratory diseases, use of antibiotics for any disease and for
Table 1
Demographic characteristics, chronic diseases and habits of the patients
Characteristics VAI*  131 (70.1%) Non-VAI  56 (29.9%) n p
Male sex 30 (42.9%) 40 (57.1%) 0.51
Age, median, y  = 71.6  = 66.4 0.67
Diabetes mellitus 24 (18.3%) 15 (26.8%) 39 (20.9%) 0.19
Arterial hypertension 67 (51.1%) 30 (53.6%) 97 (51.9%) 0.76
Copd*/asthma/ Bronchitis 18 (13.7%) 6 (10.7%) 24 (12.8%) 0.57
Pulmonary emphysema 6 (4.6%) 3 (5.4%) 9 (4.8%) 0.82
Previous pulmonary disease 25 (19.1%) 6 (10.7%) 31 (16.6%) 0.15
Hematological disease 6 (4.6%) 3 (5.4%) 9 (4.8%) 0.82
Corticosteroid use 12 (9.2%) 2 (3.6%) 14 (7.5%) 0.18
Neoplasm 7 (5.3%) 3 (5.4%) 10 (5.3%) 0.99
Smokers 49 (37.4%) 21 (37.5%) 70 (37.4%) 0.99
Alcoholism 18 (13.7%) 5 (8.9%) 23 (12.3%) 0.36
VAI*: vaccinated against influenza in 1999;  = median
Table 2
Measured outcomes according with vaccination against influenza or not in 1999
Variable VAI*  131 (70.1%) Non-VAI  56 (29.9%) n 2 or F p
ILI** 59 (45%) 27 (48%) 86 (46%) 2 = 0.16 0.69
Times of ILI  = 1.5  = 2.25 F = 5.7 0.019 ¶
Use of antibiotics 57 (43.9%) 24 (29.6%) 81 (43.3%) 2 = 0.007 0.93
Use of antibiotics for respiratory disease 25 (19.1%) 6 (26.1%) 31 (38.8%) 2 = 2.2 0.14
Hospitalization 25 (19.1%) 9 (16.1%) 34 (18.2%) 2 = 0.24 0.62
Hospitalization for respiratory disease 6 (24.0%) 1 (11.1%) 7 (20.6%) 2 = 0.67 0.41
Times of treatments for respiratory disease  = 1.20  = 1.28 F = 3.7 0.061
VAI*: vaccinated against influenza in 1999; ILI**: influenza like illness;  = median; ¶ :p significant
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treatment of respiratory disease, hospitalization in general and for
respiratory causes.
The accepted method to assess the severity of the influenza season
is estimating the excess of pneumonia and influenza (P&I) mortality.
There is a linear correlation between excess of P&I hospitalizations and
mortality rates, in USA14 . The effect of influenza in mortality varies in
different countries. REICHERT et al. states the role of influenza in
mortality in Japan is much greater than in United States12 . This difference
is probably associated with the environment and life style. It has been
hypothesized that the efficacy of the vaccination is related to the match
between the vaccine and the epidemic strains8. A study held in Argentina
showed a partial match between the circulating influenza virus and the
vaccinal strains, from 1994 to 199813.
We found an association of previous vaccination against influenza
with a reduction in the number of episodes of ILI, but not in other
measured outcomes. The use of clinically defined ILI can account, at
least partially, for the results.
The efficacy of the influenza vaccine is well established in elderly1.
In a population of working healthy adults, the efficacy and cost-
effectiveness of the vaccination against influenza are still not established3.
The vaccines are more effective in reducing the laboratory confirmed
cases of influenza than in the clinically defined cases5. Many cases of
ILI, clinically defined, as we use as an outcome, may represent, in fact,
infections caused by other agents. Laboratory-confirmed influenza
represents just part of the clinically defined ILI.
Our study can be compared to that by NICHOL et al.10 , which
targeted elderly people living in the community. But, differently from
that study, we did not find an association of influenza vaccination and
reduction of hospitalizations for respiratory diseases. This difference
may be attributed to the fact that in the study by NICHOL et al. the
vaccine recipients reported a higher proportion of coexisting diseases
than the non-vaccinated.
We did not find an association between the vaccination against
influenza and the use of antibiotics for respiratory diseases, what makes
our results different from that of CONNOLLY et al.4 , who found, in a
study from 1989, bronchitis and pneumonia the most frequent
complications of influenza.
In Brazil the annual campaign of influenza vaccination, held since
1998, is sponsored by the government. It provides free influenza vaccine
for all persons 60 years or older, health care professionals and patients
with chronic medical conditions, HIV infection and Aids. Since the
influenza vaccination in Brazil has been available for large scale use for a
few years, we can not compare our results with those found of HOSKINS
et al.7, who suggested a decreased protection after a number of annual
vaccinations. Besides, we do not have data on excess of mortality or
hospitalization associated with influenza epidemics, before 1998.
In Brazil the annual coverage of influenza vaccination in elderly is
reducing, probably because large numbers of vaccinated did not perceive
a reduction in the occurrence of influenza. Moreover misinformation
attributes to the vaccine improbable side effects.
There is a need to raise the coverage of influenza immunization in
elderly, since the vaccination is associated with a protective effect in this
population. More studies are necessary to define the role of the vaccine
in the protection of other groups in our country.
This is a retrospective study, based on information referent to the
previous year, given by elderly subjects who may not have accurately
remembered all possible influenza like illness episodes, what may have
biased the results. Despite this facts, this study suggests that inactivated
vaccine against influenza had a role in protection against influenza in
elderly Brazilians.
RESUMO
Efetividade da vacina contra influenza em população de idosos no
município de São Paulo, Brasil
Com o objetivo de investigar a efetividade da vacina contra Influenza
em população de pacientes ambulatoriais, com 60 anos e mais, no
Município de São Paulo, foram comparados retrospectivamente 187
pacientes dos quais 131 foram vacinados e 56 não foram vacinados contra
influenza em 1999. Os dois grupos foram semelhantes com respeito às
condições de saúde, características demográficas, tabagismo e alcoolismo.
No ano posterior à vacinação, os vacinados apresentaram número de
episódios clinicamente definidos como gripe, isto é, sem confirmação
laboratorial, significativamente menor do que os não vacinados. Os outros
parâmetros avaliados, a saber: ocorrência de gripe, de doença respiratória
que não gripe, hospitalização por qualquer motivo e por doença respiratória,
não diferiram nos dois grupos. Concluímos que a vacina contra influenza
contribuiu para a redução do número de episódios caracterizados como
gripe. São necessários mais estudos sobre a efetividade desta vacina em
populações idosas e outros grupos populacionais brasileiros.
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